TTRX

insider transactions

Turn Therapeutics Inc. — buys & sells by directors, officers and 10% owners (SEC Form 4).

30D 90D 1Y

No open-market buys or sells this period. The trades below are grants, option exercises and gifts, which carry no market price.

Net buy / sell volume

Tap or hover the chart for daily net volume. Green = net buying, red = net selling.

Transactions · 90d

Open-market Buys Sells All types

No open-market buys or sells in this period — showing all activity (grants, exercises & gifts).

Grant·A
Jun 4, 26

Kester Kent Edward

Director

$0

83.3K sh

Own New
Grant·A
Jun 4, 26

Gengos Andrew

Director

$0

95.0K sh

Own New
Grant·A
Jun 4, 26

GOLDEN ARTHUR F

Director

$0

89.6K sh

Own New
Grant·A
Jun 4, 26

Dewhurst Martin William

Director

$0

71.7K sh

Own New
Other·G
May 28, 26

Bradley Evan Burnam KEY

Chief Executive Officer

$0

1.2M sh · 4 lots

Own -80%
Other·G
Apr 2, 26

GOLDEN ARTHUR F

Director

$0

300.0K sh

Own -45%
Other·G
Apr 2, 26

Bradley Evan Burnam KEY

Chief Executive Officer

$0

300.0K sh

Own -2%
Grant·A
Apr 1, 26

Chaudhary Zuraiz KEY

Interim Chief Financial Offic…

$0

80.0K sh

Own New
Grant·A
Apr 1, 26

Bradley Evan Burnam KEY

Chief Executive Officer

$0

160.0K sh

Own New

Date▾	Insider	Role	Type	Shares	Own Δ	Price	Value
Jun 4, 2026	Kester Kent Edward	Director	Grant A	83.3K	New	—	$0
Jun 4, 2026	Gengos Andrew	Director	Grant A	95.0K	New	—	$0
Jun 4, 2026	GOLDEN ARTHUR F	Director	Grant A	89.6K	New	—	$0
Jun 4, 2026	Dewhurst Martin William	Director	Grant A	71.7K	New	—	$0
May 28, 2026	Bradley Evan Burnam KEY	Chief Executive Officer	Other G	1.2M4 lots	-80%	—	$0
Apr 2, 2026	GOLDEN ARTHUR F	Director	Other G	300.0K	-45%	—	$0
Apr 2, 2026	Bradley Evan Burnam KEY	Chief Executive Officer	Other G	300.0K	-2%	—	$0
Apr 1, 2026	Chaudhary Zuraiz KEY	Interim Chief Financial Officer, Vice President of Finance & Chief Accounting Officer.	Grant A	80.0K	New	—	$0
Apr 1, 2026	Bradley Evan Burnam KEY	Chief Executive Officer	Grant A	160.0K	New	—	$0

Buy Sell Non-market (grant · exercise · gift)

About TTRX insider trading

This page tracks insider transactions for Turn Therapeutics Inc. (TTRX) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.